NASDAQ:PTGX Protagonist Therapeutics Q1 2026 Earnings Report $100.88 +2.51 (+2.55%) Closing price 04:00 PM EasternExtended Trading$100.71 -0.17 (-0.17%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Protagonist Therapeutics EPS ResultsActual EPS$0.05Consensus EPS -$0.50Beat/MissBeat by +$0.55One Year Ago EPSN/AProtagonist Therapeutics Revenue ResultsActual Revenue$56.37 millionExpected Revenue$11.70 millionBeat/MissBeat by +$44.67 millionYoY Revenue GrowthN/AProtagonist Therapeutics Announcement DetailsQuarterQ1 2026Date5/5/2026TimeAfter Market ClosesConference Call DateTuesday, May 5, 2026Conference Call Time4:00PM ETUpcoming EarningsProtagonist Therapeutics' Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Protagonist Therapeutics Earnings HeadlinesFinancial Contrast: ABVC BioPharma (NASDAQ:ABVC) & Protagonist Therapeutics (NASDAQ:PTGX)May 17 at 3:53 AM | americanbankingnews.comDinesh Ph Patel Sells 75,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) StockMay 14, 2026 | americanbankingnews.comForget SpaceX. Buy the company Musk can't replace.The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks and insiders have already locked it up. But there is one small, publicly traded company that builds the critical infrastructure SpaceX cannot operate without. Dylan Jovine is releasing the ticker name today at no cost.May 20 at 1:00 AM | Behind the Markets (Ad)Analyst Forecasts For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Are Surging HigherMay 11, 2026 | finance.yahoo.comProtagonist Therapeutics, Inc. Surprised Analysts With A Profit, And Analysts Boosted Their EPS ForecastsMay 9, 2026 | finance.yahoo.comIs It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?May 7, 2026 | finance.yahoo.comSee More Protagonist Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Protagonist Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your email. Email Address About Protagonist TherapeuticsProtagonist Therapeutics (NASDAQ:PTGX) (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care. Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease. PTG-200, a selective interleukin-23 receptor antagonist, is in Phase 2 clinical trials for moderate to severe Crohn’s disease. The company’s PTG-300 program is a hepcidin mimetic being evaluated in hematologic disorders characterized by iron overload, including polycythemia vera and myelofibrosis. Founded in 2006 and headquartered in San Diego, California, Protagonist Therapeutics conducts global clinical trials across North America, Europe and Asia. The company is led by a team of seasoned biotechnology executives with deep expertise in peptide drug discovery and development. Protagonist maintains collaborations with academic institutions and industry partners to advance its pipeline and explore additional therapeutic areas where oral peptide therapeutics may deliver significant patient benefit.View Protagonist Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Analog Devices Provides Much-Needed Pullback: How Low Can It Go?USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal LoomsFrom Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 OutlookMirum Pharma: A Rare Disease Growth Story to WatchArhaus Stock Drops to 52-Week Low After Q1 EarningsWhy Home Depot’s Sell-Off Could Become a Huge OpportunityPalo Alto Networks Up 70%: Can the Rally Last Into June? Upcoming Earnings NetEase (5/21/2026)Ross Stores (5/21/2026)Walmart (5/21/2026)Deere & Company (5/21/2026)Mitsubishi UFJ Financial Group (5/21/2026)AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
